Edap Tms SA（EDAP）資訊與事件EDAPEdap Tms SA

EDAP TMS Renames to FocalTherics and Changes Ticker to FOCL

EDAP TMS announced that it will operate under the new corporate name FocalTherics to reflect its exclusive focus on high-growth robotic focal therapy. The company also announced its intention to report and classify its Extracorporeal Shock Wave Lithotripsy and Distribution operating segments as discontinued operations in the company's financial statements beginning with second quarter financial results. In conjunction with this defined focus, the company is changing its ticker symbol on Nasdaq from (EDAP) to (FOCL), effective at market open on June 1.

Telix Pharmaceuticals Enters into Collaboration Letters of Intent with EDAP and Profound Medical

Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with EDAP TMS (EDAP) and Profound Medical (PROF), companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix's commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making. The collaborations will explore the investigational use of Telix's PSMA-PET1 imaging agents Gozellix and Illuccix with robotic high-intensity focused ultrasound, or HIFU, and other image-guided therapies designed to treat localized prostate cancer, such as transurethral ultrasound ablation, or TULSA. Telix's intention is to work with select partners to explore how PSMA-PET imaging may support emerging therapy workflows, which aim to preserve healthy tissue and minimize the risk of side effects such as incontinence and impotence. Collaborative activities will focus on non-promotional scientific, educational, and research engagement.

Major Averages Rise on U.S. Iran Peace Plan

The major averages closed broadly higher following reports that the U.S. has provided a plan to Iran to bring the war to an end, which sent oil prices lower. The Associated Press reported that Iran was given a 15-point proposal from the U.S. to end the conflict, though media have reported that the two sides remain far apart on a resolution and attacks from both sides have continued.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:MerckTerns Pharmaceuticalsfor $53 per share in cashElon Musk's SpaceX will file an IPO prospectus as soon as this week or next,Armexpectsfrom its chips unit in five yearsChewyreportedand provided its outlook for Q1 and FY26JetBlueis exploring a potential merger with rivals,2. WALL STREET CALLS:Armto Outperform from Market Perform at Raymond JamesWolfeGeneral Motorson underappreciated potential tailwindsWedbushRezoluteas worst case scenario seems unlikely for cHIMondelezto Neutral from Buy at Rothschild & Co RedburnEVgowith Neutral from Overweight at JPMorgan3. AROUND THE WEB:Salesforceis skipping raises for its director-level and above employees, Insider reportsA jury found Metaand Googleliable in a social media addiction trial, Reuters saysMeanwhile, Metawill lay off "a few hundred people" across the company on Wednesday, The Information saysSK Hynixplans to spend about $8B on cutting-edge EUV lithography chipmaking tools from ASMLthrough 2027, Bloomberg saysInteland AMDhave each told customers they plan to raise prices across their entire CPU product lines starting in March and April, Nikkei reports4. MOVERS:Sareptarose after announcingfrom Phase 1/2 ascending dose studies of SRP-1001 and SRP-1003Brazegained afterand authorizing a stock repurchase program of up to $100MApogee Therapeuticsfinished higher after announcing aMaze Therapeuticsclosed lower afterand announcing data from its Phase 2 HORIZON trialAdma Biologicsfell for another session afterfrom Culper Research5. EARNINGS/GUIDANCE:Paychexand reaffirmed its guidance for FY26EDAP TMSand backed its guidance for FY26Cognyte, with EPS beating consensusCintasand raised its guidance for FY26QT Imagingand reaffirmed guidance for FY26INDEXES:The Dow rose 305.43, or 0.66%, to 46,429.49, the Nasdaq gained 167.93, or 0.77%, to 21,929.83, and the S&P 500 advanced 35.53, or 0.54%, to 6,591.90.